Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

World IP Review is set to host the highly anticipated AI and IP USA 2025, a one-day event on October 9, 2025 in New York. The ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

You successfully represented Regeneron Pharmaceuticals Inc. in Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals, Inc., in which the US District Court for the Northern District of West Virginia ...

Federal Circuit decision in appeal from Regeneron Pharms., Inc. addresses issues of personal jurisdiction, preliminary injunctions, and biopharmaceutical patent vali ...

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.

Regeneron Pharmaceuticals. has been granted a patent for methods and systems to detect abnormal karyotypes. The approach involves sequencing samples, generating quality control metrics, and analyzing ...